KRAS mutation: from undruggable to druggable in cancer
2021年11月15日 · Kirsten rat sarcoma viral oncogene homologue (KRAS) is the best-known oncogene with the highest mutation rate among all cancers and is associated with a series of highly fatal cancers,...
Targeting KRAS in cancer - Nature Medicine
2024年4月18日 · KRAS is a small membrane-bound GTP hydrolase protein that cycles between ‘on’ (GTP-loaded) and ‘off’ (GDP-unloaded) states. This cycling between the ‘on’ and ‘off’ state depends on the...
Targeting the KRAS mutation for more effective cancer …
2021年2月12日 · KRAS mutations are present in approximately 25% of tumors, making them one of the most common gene mutations linked to cancer. They are frequent drivers in lung, colorectal and pancreatic cancers. KRAS drives 32% of lung cancers, 40% of colorectal cancers, and 85% to 90% of pancreatic cancer cases.
KRAS Gene - GeneCards | RASK Protein | RASK Antibody
2024年10月2日 · KRAS (KRAS Proto-Oncogene, GTPase) is a Protein Coding gene. Diseases associated with KRAS include Schimmelpenning-Feuerstein-Mims Syndrome and Oculoectodermal Syndrome. Among its related pathways are Downstream signaling of activated FGFR2 and Prolactin Signaling.
KRAS gene - MedlinePlus
The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS/MAPK pathway. Learn about this gene and related health conditions.
What’s new in KRAS mutation research? - MD Anderson Cancer …
2024年4月4日 · Cancer cells often develop genetic mutations that initiate and sustain the growth of tumors. The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers.
Sotorasib is First KRAS Inhibitor Approved by FDA - NCI
2021年6月25日 · The CodeBreaK 100 trial, funded by Amgen and NCI, is testing sotorasib (previously called AMG510) as a treatment for people with solid tumors that have KRAS G12C. The mutation, a hallmark of damage from cigarette smoke, is most common in lung cancer.
KRAS mutation: from undruggable to druggable in cancer
2021年11月15日 · This review summarises the most recent understanding of fundamental aspects of KRAS, the relationship between the KRAS mutations and tumour immune evasion, and new progress in targeting KRAS, particularly KRAS (G12C).
KRAS and Lung Cancer - American Lung Association
2024年9月26日 · Dr. Erin Schenk explains what KRAS mutation is in lung cancer. KRAS is an important biomarker that can impact lung what treatment options. Talk to your doctor about comprehensive biomarker testing. Lung cancer survivor, Nancy, shared her advice for KRAS+ lung cancer patients.
KRAS G12C inhibitor combination therapies: current evidence and ...
This finding has led to multiple clinical trials to combine KRAS G12C inhibitors with RTK-targeted therapies predominantly for KRAS G12C-mutated CRC. Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that inhibits EGFR and is approved for CRC and head and neck cancer.
- 某些结果已被删除